NATCO Pharma Limited

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SUNPHARMA.BO trades at ₹1,836.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SUNPHARMA.BO's P/E ratio is 40.47. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUNPHARMA.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SUNPHARMA.NS trades at ₹1,840.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SUNPHARMA.NS's P/E ratio is 38.52. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUNPHARMA.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while DIVISLAB.BO trades at ₹6,729.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas DIVISLAB.BO's P/E ratio is 72.51. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to DIVISLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DIVISLAB.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while DIVISLAB.NS trades at ₹6,763.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas DIVISLAB.NS's P/E ratio is 72.14. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to DIVISLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DIVISLAB.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while TORNTPHARM.NS trades at ₹4,455.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas TORNTPHARM.NS's P/E ratio is 71.78. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to TORNTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check TORNTPHARM.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while TORNTPHARM.BO trades at ₹4,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas TORNTPHARM.BO's P/E ratio is 72.28. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to TORNTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check TORNTPHARM.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while DRREDDY.BO trades at ₹1,331.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas DRREDDY.BO's P/E ratio is 19.64. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DRREDDY.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while DRREDDY.NS trades at ₹1,328.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas DRREDDY.NS's P/E ratio is 26.45. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DRREDDY.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ZYDUSLIFE.BO trades at ₹1,078.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ZYDUSLIFE.BO's P/E ratio is 21.43. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ZYDUSLIFE.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ZYDUSLIFE.NS trades at ₹1,080.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ZYDUSLIFE.NS's P/E ratio is 21.42. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ZYDUSLIFE.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while LUPIN.NS trades at ₹2,269.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas LUPIN.NS's P/E ratio is 19.65. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to LUPIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LUPIN.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while LUPIN.BO trades at ₹2,260.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas LUPIN.BO's P/E ratio is 24.25. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LUPIN.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while MANKIND.NS trades at ₹2,424.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas MANKIND.NS's P/E ratio is 53.01. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check MANKIND.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while MANKIND.BO trades at ₹2,420.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas MANKIND.BO's P/E ratio is 52.99. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check MANKIND.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AUROPHARMA.NS has a market cap of 844.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AUROPHARMA.NS trades at ₹1,461.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AUROPHARMA.NS's P/E ratio is 24.12. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AUROPHARMA.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AUROPHARMA.BO has a market cap of 844.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AUROPHARMA.BO trades at ₹1,451.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AUROPHARMA.BO's P/E ratio is 24.68. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AUROPHARMA.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, LAURUSLABS.BO has a market cap of 733B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while LAURUSLABS.BO trades at ₹1,370.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas LAURUSLABS.BO's P/E ratio is 87.14. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LAURUSLABS.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, LAURUSLABS.NS has a market cap of 732.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while LAURUSLABS.NS trades at ₹1,374.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas LAURUSLABS.NS's P/E ratio is 87.05. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LAURUSLABS.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GLENMARK.NS has a market cap of 659.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GLENMARK.NS trades at ₹2,351.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GLENMARK.NS's P/E ratio is 61.94. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLENMARK.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GLENMARK.BO has a market cap of 659.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GLENMARK.BO trades at ₹2,344.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GLENMARK.BO's P/E ratio is 62.02. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLENMARK.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ALKEM.NS has a market cap of 645.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ALKEM.NS trades at ₹5,383.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ALKEM.NS's P/E ratio is 27.23. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALKEM.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ALKEM.BO has a market cap of 645.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ALKEM.BO trades at ₹5,356.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ALKEM.BO's P/E ratio is 27.20. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALKEM.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVENPHAR.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVENPHAR.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, IPCALAB.BO has a market cap of 399.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while IPCALAB.BO trades at ₹1,579.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas IPCALAB.BO's P/E ratio is 43.94. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IPCALAB.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, IPCALAB.NS has a market cap of 398.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while IPCALAB.NS trades at ₹1,578.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas IPCALAB.NS's P/E ratio is 43.77. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IPCALAB.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AJANTPHARM.BO has a market cap of 385.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AJANTPHARM.BO trades at ₹3,099.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AJANTPHARM.BO's P/E ratio is 38.00. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AJANTPHARM.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AJANTPHARM.NS has a market cap of 385B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AJANTPHARM.NS trades at ₹3,099.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AJANTPHARM.NS's P/E ratio is 36.46. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AJANTPHARM.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, JBCHEPHARM.NS has a market cap of 357.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while JBCHEPHARM.NS trades at ₹2,191.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas JBCHEPHARM.NS's P/E ratio is 50.07. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to JBCHEPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JBCHEPHARM.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, JBCHEPHARM.BO has a market cap of 357.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while JBCHEPHARM.BO trades at ₹2,189.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas JBCHEPHARM.BO's P/E ratio is 50.10. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JBCHEPHARM.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, EMCURE.NS has a market cap of 329.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while EMCURE.NS trades at ₹1,699.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas EMCURE.NS's P/E ratio is 35.59. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check EMCURE.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, WOCKPHARMA.BO has a market cap of 266.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while WOCKPHARMA.BO trades at ₹1,690.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas WOCKPHARMA.BO's P/E ratio is 125.33. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check WOCKPHARMA.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, WOCKPHARMA.NS has a market cap of 266.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while WOCKPHARMA.NS trades at ₹1,687.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas WOCKPHARMA.NS's P/E ratio is 125.20. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check WOCKPHARMA.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PEL.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, PPLPHARMA.NS has a market cap of 237.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while PPLPHARMA.NS trades at ₹179.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas PPLPHARMA.NS's P/E ratio is -72.95. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PPLPHARMA.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, PPLPHARMA.BO has a market cap of 237.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while PPLPHARMA.BO trades at ₹178.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas PPLPHARMA.BO's P/E ratio is -73.20. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PPLPHARMA.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ASTRAZEN.NS has a market cap of 220B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ASTRAZEN.NS trades at ₹8,948.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ASTRAZEN.NS's P/E ratio is 109.02. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ASTRAZEN.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ASTRAZEN.BO has a market cap of 219.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ASTRAZEN.BO trades at ₹8,890.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ASTRAZEN.BO's P/E ratio is 109.68. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ASTRAZEN.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, NEULANDLAB.NS has a market cap of 215B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while NEULANDLAB.NS trades at ₹17,060.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas NEULANDLAB.NS's P/E ratio is 59.05. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NEULANDLAB.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, NEULANDLAB.BO has a market cap of 214.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while NEULANDLAB.BO trades at ₹16,970.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas NEULANDLAB.BO's P/E ratio is 59.01. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NEULANDLAB.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, NATCOPHARM.BO has a market cap of 210.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while NATCOPHARM.BO trades at ₹1,175.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas NATCOPHARM.BO's P/E ratio is 13.65. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NATCOPHARM.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GRANULES.NS has a market cap of 187.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GRANULES.NS trades at ₹756.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GRANULES.NS's P/E ratio is 31.03. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GRANULES.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ERIS.NS has a market cap of 187.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ERIS.NS trades at ₹1,361.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ERIS.NS's P/E ratio is 29.89. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ERIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ERIS.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ERIS.BO has a market cap of 187.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ERIS.BO trades at ₹1,361.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ERIS.BO's P/E ratio is 29.91. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ERIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ERIS.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GRANULES.BO has a market cap of 184B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GRANULES.BO trades at ₹755.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GRANULES.BO's P/E ratio is 33.71. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GRANULES.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, COHANCE.NS has a market cap of 166.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while COHANCE.NS trades at ₹436.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas COHANCE.NS's P/E ratio is 92.72. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check COHANCE.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, COHANCE.BO has a market cap of 166.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while COHANCE.BO trades at ₹435.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas COHANCE.BO's P/E ratio is 92.71. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check COHANCE.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, JUBLPHARMA.NS has a market cap of 159.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while JUBLPHARMA.NS trades at ₹985.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas JUBLPHARMA.NS's P/E ratio is 40.19. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JUBLPHARMA.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, JUBLPHARMA.BO has a market cap of 159.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while JUBLPHARMA.BO trades at ₹989.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas JUBLPHARMA.BO's P/E ratio is 40.09. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JUBLPHARMA.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, CAPLIPOINT.NS has a market cap of 157.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while CAPLIPOINT.NS trades at ₹2,036.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas CAPLIPOINT.NS's P/E ratio is 24.69. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check CAPLIPOINT.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, CAPLIPOINT.BO has a market cap of 157.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while CAPLIPOINT.BO trades at ₹2,035.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas CAPLIPOINT.BO's P/E ratio is 24.65. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check CAPLIPOINT.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, APLLTD.BO has a market cap of 149.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while APLLTD.BO trades at ₹758.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas APLLTD.BO's P/E ratio is 22.24. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check APLLTD.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, APLLTD.NS has a market cap of 149.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while APLLTD.NS trades at ₹759.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas APLLTD.NS's P/E ratio is 22.22. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check APLLTD.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLS.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLS.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ALIVUS.NS has a market cap of 128.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ALIVUS.NS trades at ₹1,086.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ALIVUS.NS's P/E ratio is 22.86. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALIVUS.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ALIVUS.BO has a market cap of 128.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ALIVUS.BO trades at ₹1,086.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ALIVUS.BO's P/E ratio is 22.86. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALIVUS.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, VIYASH.NS has a market cap of 113.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while VIYASH.NS trades at ₹257.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas VIYASH.NS's P/E ratio is 65.08. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check VIYASH.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, STAR.BO has a market cap of 109.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while STAR.BO trades at ₹1,173.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas STAR.BO's P/E ratio is 19.69. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check STAR.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, STAR.NS has a market cap of 109.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while STAR.NS trades at ₹1,173.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas STAR.NS's P/E ratio is 19.70. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check STAR.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check CAPPL.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SHILPAMED.NS has a market cap of 100.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SHILPAMED.NS trades at ₹508.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SHILPAMED.NS's P/E ratio is 41.14. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SHILPAMED.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, PGHL.NS has a market cap of 95B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while PGHL.NS trades at ₹5,661.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas PGHL.NS's P/E ratio is 40.12. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PGHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PGHL.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, PGHL.BO has a market cap of 95B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while PGHL.BO trades at ₹5,692.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas PGHL.BO's P/E ratio is 40.19. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PGHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PGHL.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AKUMS.NS has a market cap of 79.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AKUMS.NS trades at ₹532.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AKUMS.NS's P/E ratio is 31.22. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AKUMS.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SUDEEPPHRM.NS has a market cap of 78.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SUDEEPPHRM.NS trades at ₹698.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SUDEEPPHRM.NS's P/E ratio is 46.83. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUDEEPPHRM.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SPARC.BO has a market cap of 75.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SPARC.BO trades at ₹237.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SPARC.BO's P/E ratio is 4.87. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SPARC.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SPARC.NS has a market cap of 75.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SPARC.NS trades at ₹238.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SPARC.NS's P/E ratio is 4.87. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SPARC.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AARTIPHARM.BO has a market cap of 66.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AARTIPHARM.BO trades at ₹695.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AARTIPHARM.BO's P/E ratio is 31.12. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIPHARM.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AARTIPHARM.NS has a market cap of 66.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AARTIPHARM.NS trades at ₹697.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AARTIPHARM.NS's P/E ratio is 31.13. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIPHARM.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SUVEN.BO has a market cap of 62.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SUVEN.BO trades at ₹274.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SUVEN.BO's P/E ratio is -22.02. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVEN.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SUVEN.NS has a market cap of 60.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SUVEN.NS trades at ₹275.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SUVEN.NS's P/E ratio is -22.34. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVEN.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, FDC.BO has a market cap of 60.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while FDC.BO trades at ₹404.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas FDC.BO's P/E ratio is 27.84. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check FDC.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, FDC.NS has a market cap of 60.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while FDC.NS trades at ₹403.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas FDC.NS's P/E ratio is 27.79. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check FDC.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SEQUENT.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SEQUENT.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SHILPAMED.BO has a market cap of 50.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SHILPAMED.BO trades at ₹498.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SHILPAMED.BO's P/E ratio is 41.22. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SHILPAMED.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, INNOVACAP.NS has a market cap of 48.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while INNOVACAP.NS trades at ₹849.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas INNOVACAP.NS's P/E ratio is 34.76. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check INNOVACAP.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GUJTHEM.NS has a market cap of 42.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GUJTHEM.NS trades at ₹368.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GUJTHEM.NS's P/E ratio is 88.69. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GUJTHEM.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, RPGLIFE.BO has a market cap of 37.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while RPGLIFE.BO trades at ₹2,211.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas RPGLIFE.BO's P/E ratio is 18.42. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check RPGLIFE.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, RPGLIFE.NS has a market cap of 37.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while RPGLIFE.NS trades at ₹2,220.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas RPGLIFE.NS's P/E ratio is 18.40. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check RPGLIFE.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, IOLCP.BO has a market cap of 36.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while IOLCP.BO trades at ₹136.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas IOLCP.BO's P/E ratio is 31.41. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IOLCP.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, IOLCP.NS has a market cap of 36.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while IOLCP.NS trades at ₹135.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas IOLCP.NS's P/E ratio is 31.39. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IOLCP.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ORCHPHARMA.BO has a market cap of 36.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ORCHPHARMA.BO trades at ₹720.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ORCHPHARMA.BO's P/E ratio is 189.83. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ORCHPHARMA.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, ORCHPHARMA.NS has a market cap of 36.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while ORCHPHARMA.NS trades at ₹724.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas ORCHPHARMA.NS's P/E ratio is 191.27. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ORCHPHARMA.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AARTIDRUGS.NS has a market cap of 36B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AARTIDRUGS.NS trades at ₹395.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AARTIDRUGS.NS's P/E ratio is 18.46. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIDRUGS.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, AARTIDRUGS.BO has a market cap of 36B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while AARTIDRUGS.BO trades at ₹398.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas AARTIDRUGS.BO's P/E ratio is 18.46. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIDRUGS.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, NOVARTIND.BO has a market cap of 33.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while NOVARTIND.BO trades at ₹1,423.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas NOVARTIND.BO's P/E ratio is 36.08. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NOVARTIND.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, BLISSGVS.BO has a market cap of 33.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while BLISSGVS.BO trades at ₹381.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas BLISSGVS.BO's P/E ratio is 26.44. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check BLISSGVS.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, BLISSGVS.NS has a market cap of 33.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while BLISSGVS.NS trades at ₹381.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas BLISSGVS.NS's P/E ratio is 26.44. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check BLISSGVS.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, NOVARTIND.NS has a market cap of 33.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while NOVARTIND.NS trades at ₹1,426.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas NOVARTIND.NS's P/E ratio is 36.10. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NOVARTIND.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GUFICBIO.BO has a market cap of 32.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GUFICBIO.BO trades at ₹316.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GUFICBIO.BO's P/E ratio is 65.26. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GUFICBIO.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, GUFICBIO.NS has a market cap of 32.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while GUFICBIO.NS trades at ₹318.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas GUFICBIO.NS's P/E ratio is 65.14. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GUFICBIO.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SOLARA.BO has a market cap of 26.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SOLARA.BO trades at ₹556.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SOLARA.BO's P/E ratio is -114.96. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SOLARA.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, SOLARA.NS has a market cap of 26.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while SOLARA.NS trades at ₹556.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas SOLARA.NS's P/E ratio is -114.99. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SOLARA.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, HIKAL.NS has a market cap of 26.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while HIKAL.NS trades at ₹216.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas HIKAL.NS's P/E ratio is -200.06. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check HIKAL.NS's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, HIKAL.BO has a market cap of 26.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while HIKAL.BO trades at ₹215.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas HIKAL.BO's P/E ratio is 267.06. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check HIKAL.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, UNICHEMLAB.BO has a market cap of 25.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while UNICHEMLAB.BO trades at ₹356.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas UNICHEMLAB.BO's P/E ratio is 8.65. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check UNICHEMLAB.BO's competition here

NATCOPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 210.1B. In comparison, UNICHEMLAB.NS has a market cap of 25.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹1,188.70, while UNICHEMLAB.NS trades at ₹357.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 13.50, whereas UNICHEMLAB.NS's P/E ratio is 8.60. In terms of profitability, NATCOPHARM.NS's ROE is +0.20%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check UNICHEMLAB.NS's competition here